United Therapeutics (UTHR) Earnings Date & Reports

Key Takeaways

• United Therapeutics reported Q4 2025 revenue of $790.2 million, up 7% year-over-year but missing consensus estimates of approximately $815 million.
• Diluted EPS came in at $7.70, surpassing expectations of $6.78 by 13.5% and rising 24% from $6.19 in Q4 2024.
• Full-year 2025 revenue hit a record $3.18 billion, up 11% from 2024, driven by Tyvaso and Orenitram growth.
• Tyvaso sales reached $464.3 million in Q4, up 12%, with Tyvaso DPI surging 24% to $338.6 million.
• Orenitram revenue grew 12% to $121.2 million; company reaffirmed double-digit revenue growth outlook for 2026.
• Shares surged over 11% in pre-market trading post-earnings, reflecting optimism despite revenue miss.

Earnings Context and Why It Matters

United Therapeutics Corporation (UTHR), a leader in therapies for pulmonary arterial hypertension (PAH), released its Q4 and full-year 2025 results on February 25, 2026. This report caps a transformative year where the company surpassed $3 billion in annual revenue for the first time, underscoring robust demand for its flagship products amid a growing PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD) market. Investors closely watch these earnings for insights into Tyvaso franchise momentum, especially post-Inflammation Reduction Act (IRA) changes boosting commercial utilization, and pipeline progress in organ manufacturing and new indications. Strong profitability amid R&D investments signals sustainability, making this a pivotal gauge for UTHR's expansion in rare lung diseases.

Reported Results

United Therapeutics posted Q4 2025 total revenues of $790.2 million, a 7% increase from $735.9 million in Q4 2024, but below consensus estimates around $815 million. Key drivers included Tyvaso at $464.3 million (up 12%), led by Tyvaso DPI's $338.6 million (up 24% on higher volumes), offset by a 12% drop in nebulized Tyvaso to $125.7 million. Orenitram rose 12% to $121.2 million, while Remodulin dipped 5% to $128.0 million (including Remunity pumps). Unituxin fell 8% to $62.3 million.

Net income reached $364.3 million, with diluted EPS of $7.70, beating Zacks Consensus of $6.78 and up 24% year-over-year. Full-year revenue hit $3.18 billion (up 11%), with diluted EPS at $27.86 (up from $24.64). No formal Q1 2026 guidance was issued, but management reaffirmed expectations for double-digit revenue growth in 2026 and a $4 billion annualized run-rate by H2 2027, fueled by Tyvaso expansions.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions in dynamic markets. Explore the AI Screener today to uncover potential opportunities like those in biotech leaders such as UTHR.

Market Reaction and Investor Sentiment

Despite the revenue shortfall, UTHR shares jumped 11.73% in pre-market trading to around $477 on February 25, 2026, and continued rising toward $526, nearing 52-week highs. Investors prioritized the EPS beat, record full-year revenue, and optimistic outlook over the top-line miss, boosting sentiment. Positive Tyvaso growth and reaffirmed double-digit 2026 guidance overshadowed concerns, with analysts noting strong commercial execution in a competitive PAH landscape.

Forward Outlook and Key Factors to Monitor

Following Q4 results, United Therapeutics eyes sustained double-digit revenue growth in 2026, targeting a $4 billion annualized run-rate by the second half of 2027. This hinges on Tyvaso franchise expansion, particularly DPI adoption in PAH and PH-ILD patients, amid favorable IRA-driven utilization shifts.

Pipeline catalysts loom large: Phase 3 ADVANCE OUTCOMES trial results for Tyvaso in PH-ILD expected soon, alongside TETON-1 data for idiopathic pulmonary fibrosis (IPF) in Q2 2026. Positive outcomes could prompt supplemental NDA filings by summer 2026, broadening addressable markets significantly.

Commercial metrics warrant attention, including patient adds for Orenitram and Remunity pump uptake (subcutaneous Remodulin delivery). Cost pressures from royalties and R&D ($550 million in 2025) remain, but $4.7 billion in cash supports buybacks ($2 billion in 2025) and innovation in organ manufacturing.

Broader dynamics include generic risks for older products and payer dynamics post-IRA. Upcoming conferences like Leerink Global Healthcare in March 2026 may offer updates.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations